Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.56% 0.06% 1.190B 36432.40
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (Since Inception)
0% 39.00% -216.40M Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE ® Arca ® Biotechnology Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust Advisors L.P.
Prospectus Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Lindquist 17.63 yrs
David McGarel 17.63 yrs
Jon Erickson 17.63 yrs
Roger Testin 17.63 yrs
Stan Ueland 17.24 yrs
Chris Peterson 7.88 yrs
Erik Russo 3.09 yrs

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of February 28, 2024. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Loading chart...
Name
2017
2018
2019
2020
2021
2022
2023
YTD
37.07%
-0.30%
19.74%
12.96%
-3.59%
-4.83%
2.55%
-3.45%
22.40%
-8.71%
27.67%
15.90%
21.82%
-18.14%
23.79%
5.02%
21.08%
-9.53%
25.21%
26.01%
0.95%
-13.69%
3.76%
2.63%
21.82%
-1.33%
22.26%
28.00%
15.20%
-12.24%
-4.53%
3.41%
--
--
--
65.01%
-0.23%
-33.72%
-2.94%
0.08%
--
--
--
--
--
-25.84%
4.50%
-2.29%
As of February 28, 2024.

Asset Allocation

As of February 27, 2024.
Type % Net % Long % Short
Cash 0.06% Upgrade Upgrade
Stock 99.94% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE ® Arca ® Biotechnology Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust Advisors L.P.
Prospectus Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Lindquist 17.63 yrs
David McGarel 17.63 yrs
Jon Erickson 17.63 yrs
Roger Testin 17.63 yrs
Stan Ueland 17.24 yrs
Chris Peterson 7.88 yrs
Erik Russo 3.09 yrs

Top Portfolio Holders

0 of 0